Immunovant to report Q2 2026 financial results and business update on Nov 9

Immunovant, a clinical-stage immunology company, will announce its financial results for the second fiscal quarter ending September 30, 2026, on November 9 before the market opens. Roivant Sciences, its majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET the same day, providing a business update. Investors can access the call via registration online, and the webcast will be archived on Immunovant's website. This update is important as it offers insights into the company's progress in developing therapies for autoimmune diseases using anti-FcRn technology.

As Immunovant prepares to report its Q2 fiscal results on November 9, its stock is currently priced at USD 28.48 on Pluang, down 0.38% as of October 21, 2026, 18:11 WIB. Meanwhile, Roivant Sciences, the majority shareholder, sees its shares trading at USD 36.91, up 5.70% on the same date and time. This snapshot provides a current market context ahead of the upcoming financial update.